For instance, elesclomol (ES) directly targets FDX1 and inhibits FDX1-mediated Fe-S cluster biosynthesis, thereby promoting copper-dependent cell death in human breast cancer and lung adenocarcinoma cells (Tsvetkov et al., 2019). This evidence concerns the gene FDX1 and breast carcinoma.